First Puberty Blocker Prescribed for Gender Dysphoria
Clinicians at the VU Medical Center in Amsterdam prescribed the GnRH agonist triptorelin to a young patient experiencing gender dysphoria, marking the first known clinical use of puberty blockers for this purpose. The pioneering case, documented by Peggy Cohen-Kettenis and Stephanie van Goozen, laid the groundwork for what would become the influential Dutch Protocol for treating adolescent gender dysphoria.
Impact & Significance
Established a new medical approach to adolescent gender dysphoria that would be adopted by clinics worldwide over the following two decades, fundamentally changing the landscape of trans youth healthcare.
Reference Record
- Date
- 1998
- Era
- 1990-1999
- Sources
- 2
This timeline entry is being migrated into the reference platform. Source metadata and editorial review status will be strengthened as each topic is upgraded.
